Genipin

Summary

Genipin (CHEMBL459016) is a phase-3 clinical-stage small molecule; indicated across 1 condition including disease of the tendon.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 226.23 Da · C11H14O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL459016
Name	Genipin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	442424
Molecular formula	C11H14O5
Molecular weight	226.23
InChIKey	AZKVWQKMDGGDSV-BCMRRPTOSA-N

SMILES: COC(=O)C1=CO[C@H]([C@H]2[C@@H]1CC=C2CO)O

IUPAC name: methyl (1R,4aS,7aS)-1-hydroxy-7-(hydroxymethyl)-1,4a,5,7a-tetrahydrocyclopenta[c]pyran-4-carboxylate

Also known as: Genipin, genipin, SID90341485, GENIPIN

Patent coverage: 4,953 distinct patent families (10,803 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
disease of the tendon	3	MONDO:0100010	MONDO:0004857

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05755750	PHASE3	COMPLETED	Intratendinous Genipin Injection in Horses With Tendon Injuries

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).